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Background and Aim: Oral bisphosphonates have been shown to reduce the risk of fractures 
in patients with osteoporosis. It can be assumed that the clinical effectiveness of oral bisphos-
phonates depends on persistence with therapy.
Methods: The inﬂ  uence of persistence with and adherence to oral bisphosphonates on frac-
ture risk in a real-life setting was investigated. Data from 4451 patients with a deﬁ  ned index 
prescription of bisphosphonates were included. Fracture rates within 180, 360, and 720 days 
after index prescription were compared between persistent and non-persistent patients. In an 
extended Cox regression model applying multiple event analysis, the inﬂ  uence of adherence 
was analyzed. Persistence was deﬁ  ned as the duration of continuous therapy; adherence was 
measured in terms of the medication possession ratio (MPR).
Results: In patients with a fracture before index prescription, fracture rates were reduced by 
29% (p = 0.025) comparing persistent and non-persistent patients within 180 days after the 
index prescription and by 45% (p   0.001) within 360 days. The extended Cox regression 
model showed that good adherence (MPR   0.8) reduced fracture risk by about 39% (HR 0.61, 
95% CI 0.47–0.78; p   0.01).
Conclusions: In patients with osteoporosis-related fractures, good persistence and adherence 
to oral bisphosphonates reduced fracture risk signiﬁ  cantly.
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Introduction
Osteoporosis is characterized by a low bone density and deterioration of bone tissue, 
associated with an increased risk of fractures. International guidelines on treatment and 
prevention of osteoporosis recommend the use of bisphosphonates such as alendronate 
and risedronate.1 Currently, compounds are available as an oral daily regimen or as 
single tablet taken once a week. Recently, preparations have become available which 
can be given either orally once a month or administered parenterally every 3 months 
or yearly. In clinical trials, oral bisphosphonates have been shown to reduce the risk 
of fractures in patients with osteoporosis.2
In clinical practice, however, a low persistence probably limits this effect. Obser-
vational studies demonstrate that good compliance is associated with a reduced risk 
of fracture.3–5 Osteoporosis, as a chronic condition, necessitates regular use of medica-
tion, but the precautions detailed in the dosing instructions of oral bisphosphonates 
(ie, remaining upright for 30 min) may reduce adherence. Thus, persistence and 
adherence are crucial elements in determining the success of any long-term therapy 
for osteoporosis.
The focus of this study was on the inﬂ  uence of persistence with and adherence to 
bisphosphonates on fracture risk in patients with osteoporosis in a naturalistic setting. Patient Preference and Adherence 2009:3 26
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Therefore, we compared fracture rates in patients with 
osteoporosis according to persistence and adherence within 
180, 360, and 720 days after index prescription.
Material and methods
Data and time frame
In order to build a cohort for a retrospective cohort study, we 
extracted data from a claims database of a German statutory 
sickness fund, covering about 1.4 million lives. Data recorded 
from 2000 to 2004 were considered.
The database covers information on demographic vari-
ables (age and gender), enrollment period, hospitalization 
including diagnoses (ICD-10 code), admission and discharge 
date, sick leave including diagnoses (ICD-10 code) and 
related number of days absent from work, and outpatient 
prescription data. The prescription data contains the national 
drug code (PZN: Pharmazentralnummer) and date of ﬁ  lled 
prescriptions. The PZN code provides information on active 
substance, package size (ie, number of pills), and dosage 
strength. The anonymity of the insurance data was protected 
by the use of pseudonyms.
Identiﬁ  cation of the study cohort
We identiﬁ  ed patients enrolled in the health plan between 
2000 and 2004 for at least 90 days and aged  45 years. 
Inclusion was restricted to patients with at least one 
prescription of an oral bisphosphonate (according to PZN 
code) indicated for treatment of osteoporosis in Germany 
(alendronate, risedronate, etidronate). Patients with a 
recorded diagnosis of cancer, AIDS or Paget`s disease 
were excluded. An index prescription was defined as 
the ﬁ  rst prescription of alendronate or risedronate (ﬁ  rst 
prescriptions of etidronate were not considered because of 
the low percentage of this compound in the market) with an 
observation time of at least 360 days before and 180 days 
after the index prescription, and which met the criteria of no 
prescription of any bisphosphonate within 180 days before 
the corresponding index date. Thus we included patients with 
as well as without previous fractures.
Statistical analysis
Primary end points of the study were incident fractures. 
Fracture rates of patient with or without a previous fracture 
(before index prescription) within 180, 360, and 720 days after 
the index prescription were compared between persistent and 
non-persistent patients. Patients were classiﬁ  ed as “persistent” 
if the therapy duration was at least as long as the time period 
considered. In an extended Cox regression model, time to 
osteoporosis-related fractures was analyzed using survival 
analysis techniques like Kaplan-Meier estimates and Cox 
regression analysis. Persistence was deﬁ  ned as the dura-
tion of continuous therapy after the indicated period of time 
starting from the index prescription. Prescription gaps longer 
than 30 days were deﬁ  ned as discontinuation of therapy, but 
neither switches between alendronate and risedronate or to 
etidronate, nor switches between daily and weekly intake were 
considered as a discontinuation. Adherence was measured in 
terms of the medication possession ratio (MPR), deﬁ  ned as 
days supplied with medication in percentage of therapy dura-
tion. Beneﬁ  ciaries with a MPR   0.8 were considered to be 
adherent, that is, if they had medication available during 80% 
or more of the deﬁ  ned time interval. Recurrent event analysis 
was performed with the MPR as a time-dependent variable 
to account for all fractures that could be observed during the 
observation period. Diagnoses of the following fractures were 
considered: fracture of femur (including hip; S72); fracture of 
wrist and hand level (S62); fracture of lumbar vertebra (S32); 
fracture of thoracic vertebra (S22); fracture of forearm (S52); 
and fracture of shoulder and upper arm (S42). Diagnoses 
were included in cases of sick leave as well as hospital stays. 
It was not possible to distinguish between clinical and non 
clinical fractures.
Results
Baseline characteristics and study cohort
We identiﬁ  ed 594,795 (255,509 women, 43.0%) beneﬁ  ciaries 
of the sickness fund who were at least 45 years old and insured 
for at least 90 days within the 5-year study period. Of these, 
4451 patients received an index prescription of alendronate or 
risedronate (Table 1). A total of 3289 were women (73.9%), 
and about half of the patients with an index prescription 
(n = 2414; 54.2%) were between 66 and 85 years old.
Of the patients with an index prescription, 3642 (81.8%) 
were observed for at least 360 days and 2094 (47.0%) for at 
least 720 days after the index prescription date. Most of the 
patients were those without a previous fracture (Table 2). 
In total, 31.6% of the patients with at least 180 days of 
observation time and 37.7% of the patients with at least 
720 days of observation time had an incident fracture. The 
proportion of patients with an incident fracture was higher 
in patients with previous fractures.
Inﬂ  uence of persistence and adherence 
on fracture risk
Table 3 shows that in patients with a previous fracture, fracture 
rates were reduced by 29% (p = 0.025) when comparing Patient Preference and Adherence 2009:3 27
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persistent (n = 237) and non-persistent patients (n = 110) 
within 180 days (ie, observation time 360 days before and 
180 days after index prescription). In the subsample of 
298 patients with previous fractures surveyed for 360 days 
(ie, observation time 360 days before and 360 days after index 
prescription), persistent use (n = 141) of bisphosphonates was 
associated with a 45% lowered risk of fractures (p   0.001) 
compared to non-persistent users. Within 720 days a 
nonsigniﬁ  cant reduction of 9% (p = 0.752) was observed 
when comparing persistent (n = 23) and non-persistent users 
(n = 136).
In patients without previous fracture, low incident 
fracture rates made it difﬁ  cult to demonstrate a signiﬁ  cant 
effect. However, within 720 days after the index prescription, 
a nonsigniﬁ  cant reduction of 11% (p = 0.709) in fracture rates 
was observed in persistent patients (n = 346) compared with 
non-persistent patients (n = 1589).
The effect of adherence on the fracture risk was examined 
using an extended Cox regression model (Table 4). A good 
adherence (MPR   0.8) reduced the fracture risk by about 
39% in all patients (HR 0.61, 95% CI 0.47–0.78; p   0.01). 
The fracture risk was signiﬁ  cantly increased in patients with a 
previous fracture (HR 10.32, 95% CI 8.09–13.16; p   0.001) 
and in beneﬁ  ciaries elder than 65 years (HR 1.61 95% 
CI 1.24–2.07; p   0.001). None of the other variables (prior 
use of glucocorticoids, gender) signiﬁ  cantly affected the 
fracture risk.
The proportion of adherent patients is shown in Table 5. 
Adherence was higher in patients with a previous fracture. 
In patients with a previous fracture as well as in patients 
without previous fracture the proportion of adherent patients 
declined with observation time.
Discussion
Osteoporotic fractures are one of the most common causes 
for chronic disability.4 In clinical studies, continuous therapy 
with oral bisphosphonates was shown to reduce the risk of 
fractures in osteoporotic patients, but little is known about the 
inﬂ  uence of suboptimal usage in clinical practice. Therefore, 
we analyzed the inﬂ  uence of persistence and adherence on 
fracture risk in 4451 patients with an index prescription of 
bisphosphonates in a naturalistic setting.
The results showed that persistence with oral bisphospho-
nates was generally poor. The fracture risk was signiﬁ  cantly 
increased in beneﬁ  ciaries who had a previous fracture and in 
beneﬁ  ciaries elder than 65 years. However, in patients with 
previous osteoporosis-related fractures, good persistence with 
and adherence to oral bisphosphonates reduced fracture risk 
signiﬁ  cantly. The effect could be observed within 180 and 
360 days after onset of therapy. Reduction of fracture rates 
in persistent patients was more pronounced in beneﬁ  ciaries 
with previous fractures within 360 before the prescription 
of bisphosphonates.
We measured adherence in terms of the MPR. Two 
points should be considered while analyzing the effect of 
Table 1 Distribution of age and gender among patients with an 
index prescription (patients with observation time of at least 
360 days before and 180 days after index prescription, n = 4451)
Age group Men Women Total
n% n% n%
45–65 699 15.7 1227 27.6 1926 43.3
66–85 451 10.1 1963 44.1 2414 54.2
 85 12 0.3 99 2.2 111 2.5
Total 1162 26.1 3289 73.9 4451 100.0
Table 2 Number of patients with and without previous fractures within 360 days before the index prescription in the sub samples with 
at least 180, 360, and 720 days observation time, respectively
Women Men Total













180 days, n = 4451 285 (6.4) 3004 (67.5) 98 (2.2) 1064 (23.9) 383 (8.6) 4068 (91.4)
360 days, n = 3642 219 (6.0) 2456 (67.4) 79 (2.2) 888 (24.4) 298 (8.2) 3344 (91.8)
720 days, n = 2094 117 (5.6) 1388 (66.3) 42 (2.0) 547 (26.1) 159 (7.6) 1935 (92.4)
Patients with incident fracture
180 days, n = 4451 87 (30.5) 0 (0.0) 34 (34.7) 0 (0.0) 121 (31.6) 0 (0.0)
360 days, n = 3642 78 (35.6) 41 (1.7) 31 (39.2) 10 (1.1) 109 (36.6) 51 (1.5)
720 days, n = 2094 39 (33.3) 52 (3.7) 21 (50.0) 16 (37.7) 60 (37.7) 68 (3.5)Patient Preference and Adherence 2009:3 28
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adherence: (i) adherence changes over time in individual 
patients;5 (ii) patients often experience more than one fracture 
during the observation period, thus it would be more correct 
to account for all fractures that could be observed. Therefore, 
a recurrent event analysis was performed with MPR as a 
time-dependent variable.
The underlying claims database contains data collected 
routinely from the ambulatory and the inpatient setting with 
all prescriptions and all hospital stays recorded. The data 
have been recorded for billing purposes and have not been 
inﬂ  uenced by a study or any selection bias. Compared with 
randomized controlled trials (RCTs), studies based on claims 
data reﬂ  ect a real-life setting.
We performed a retrospective cohort study, which may 
have several limitations. Our analyses may be limited by 
some factors related to our database: the underlying database 
is not representative of the general population. Beneﬁ  ciaries 
of the sickness fund are younger than the general population 
(72.2% aged between 45 and 54 years) and men are slightly 
over-represented (57.0%). Data on important risks of 
osteoporosis are not available in our database, especially 
information on weight, bone mineral density, or health-
related behavior such as smoking and physical activity. There 
also may be some limitation due to data recovery, although 
we think that the possible bias is low: The routine data do 
cover all prescriptions which are dispensed in a pharmacy 
as well as all hospital stays of the patients. Therefore, no 
clinical fracture should have been missed. Because we have 
included all diagnoses of hospital stays and sick leave cases 
(main diagnosis as well as additional diagnoses), we cannot 
eliminate the possibility that some fractures were only radio-
graphic and not clinical.
Table 4 Extended Cox regression model of incident fractures
Parameter Hazard ratio p-value 95% CI
MPR  0.8 (non-adherent) 1.00
 0.8 (adherent) 0.61 0.00 0.47 0.78
Age group  65 0.00
66–85 1.61 0.00 1.24 2.07




yes 10.32 0.00 8.09 13.16
Gender Men 1.00




Yes 1.23 0.17 0.91 1.65
Table 3 Beneﬁ  ciaries with previous fractures before the index prescription: fracture rates within 180 days (n = 383), 360 days (n = 298) 
and 720 (n = 159), respectively according to persistence
Without previous fracture With previous fracture Reduction  p-value
n%n %%
Subsample 180 days, n = 383
Non-persistent, n = 110 66 60.0 44 40.0
29.5 0.025
Persistent, n = 273 196 71.8 77 28.2
Subsample 360 days, n = 298
Non-persistent, n = 157 84 53.5 73 46.5
45.1  0.001
Persistent, n = 141 105 74.5 36 25.5
Subsample 720 days, n = 159
Non-persistent, n = 136 84 61.8 52 38.2
9.0 0.752
Persistent, n = 23 15 65.2 8 34.8Patient Preference and Adherence 2009:3 29
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For the following reasons, we did not differentiate between 
the drugs used: i) We only considered drugs approved for 
the therapy of osteoporosis. Patients with other diseases 
enhancing the fracture risk (cancer, Morbus Paget, AIDS) 
were excluded. ii) The proportion of etidronate in the German 
market is marginal. ii) The current German guideline for the 
diagnosis and therapy of osteoporosis does not indicate any 
difference between alendronate and risedronate considering 
the reduction of fracture risk.10 Therefore, we assume that we 
included only patients with a bisphosphonate therapy for the 
prevention of osteoporosis related fractures.
Due to the relatively low rate of fractures in patients 
without known fractures at study entry, in further studies a 
longer follow-up of patients with continuous oral bisphospho-
nate therapy may be necessary to show a signiﬁ  cant fracture 
reduction by therapy in this subgroup.
Until now, only a few studies evaluated the relation-
ship between compliance and persistence with bisphospho-
nates on fracture risk in clinical practice, predominantly in 
postmenopausal women. Despite methodological differences, 
our results are consistent with ﬁ  ndings of other studies that 
report decreased fracture risks in compliant patients.3–5 In a 
study among 35,537 women with a minimum age of 45 years, 
a 21% reduction in fracture risk in compliant women was 
observed compared to non-compliant patients (p   0.001).6 
Similarly, further studies presented in a review by Seeman et al7 
showed that the probability of sustaining a fracture is higher 
in poor compliers. Our results are also in line with the results 
of a nested case-control study reporting that positive effects of 
bisphosphonate therapy can be observed within 180 days after 
onset of therapy.8 Our observations are similar to those reported 
in a retrospective study investigating the impact of compli-
ance and adherence on fracture risk. In the study published by 
Rabenda et al9 the MPR was a signiﬁ  cant predictor of incident 
fractures, the relative risk reduction for hip fracture was 60% in 
persistent versus non-persistent patients (p   0.0001).
There have been already similar studies on the prevention 
of osteoporosis related fractures (eg,11), which have shown 
the effectiveness of bisphosphonate therapy on fracture risk 
reduction. Our analysis shows, that the effectiveness is not 
only true for the setting of an RCT, but also the real-life 
setting. Moreover, our analysis focused on the inﬂ  uence 
of persistence and adherence to bisphosphonate therapy on 
fracture risk.
In conclusion, our results conﬁ  rm that in actual practice 
improving adherence and persistence with bisphosphonates 
may reduce the risk of osteoporotic fractures in patients with 
fracture history.
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